Hikma Publishes Transcript of R&D Spotlight on Respiratory, Nasal, Semi-Solids and Liquids

By Public Technologies
  • Hikma’s October 20, 2026, respiratory, nasal, semi-solids and liquids R&D spotlight featured global R&D head Hafrun Fridriksdottir and platform head Chris Edlin.
  • Intranasal epinephrine is under US regulatory review, with FDA feedback expected in the first half of 2027.
  • Respimat submission timing has slipped following technical challenges, but management does not expect a material impact on launches targeted around patent expiry.
  • The Ellipta program has generated human data supporting device selection; commercial manufacturing capability is being established in Columbus.
  • Higher R&D investment targets opportunities across three platforms, including a greater focus on first-to-file and first-to-market solid oral products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.